GSK execs take financial and medical reins at Adaptimmune
This article was originally published in Scrip
Executive Summary
Adaptimmune, a clinical-stage biotechnology company focused on the use of T-cell therapy to treat cancer, has named Dr Rafael Amado chief medical officer and Adrian Rawcliffe chief financial officer – effective from 16 March 2015.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.